Introduction
============

Classic experiments by Alfred Jost in fetal rabbits identified a Müllerian inhibitor associated with the testis that was required for the regression of the Müllerian ducts \[[@dvz017-B1], [@dvz017-B2]\]. The Müllerian inhibitor was subsequently identified as anti-Müllerian hormone (AMH), also known as Müllerian inhibiting substance (MIS) or factor (MIF) \[[@dvz017-B3]\]. Molecular studies led to the cloning of the genes encoding AMH and its type II receptor (AMHR2) \[[@dvz017-B4]\]. Human studies have identified mutations in the *AMH* and *AMHR2* genes, leading to a condition known as persistent Müllerian duct syndrome (PMDS), a rare recessive intersex condition \[[@dvz017-B8]\]. Males with PMDS have a uterus and fallopian tubes and can have testicular descent abnormalities. Mutations in these two genes have been shown to result in PMDS in human, mouse, and dog \[[@dvz017-B9]\]. In addition, gene knockout studies in mice have led to the identification of *Amh*, *Amhr2*, and other genes required for Müllerian duct regression ([Table 1](#dvz017-T1){ref-type="table"}). Together, there is now sufficient information to describe the first gene regulatory network (GRN) for Müllerian duct regression. This GRN should provide a useful framework to understand the genetic interactions that lead to Müllerian duct regression, sex differentiation, and its relationship to environmental influences.

###### 

genes that participate in AMH GRN for Müllerian duct regression

  Gene                        Mutation                          Phenotype               Reference
  --------------------------- --------------------------------- ----------------------- ---------------------------------------------------------------------------------------------------------
  *Acvr1*                     Conditional KO                    Normal MD regression    Orvis *et al.* \[[@dvz017-B36]\]
  *Amh*                       Null                              PMDS                    Behringer \[[@dvz017-B21]\]; Arango *et al.* \[[@dvz017-B22]\]
  *Amhr2*                     Null                              PMDS                    Mishina *et al.* \[[@dvz017-B30]\]; Jamin *et al.* \[[@dvz017-B31]\]; Arango *et al.* \[[@dvz017-B17]\]
  *Bmpr1a*                    Conditional KO                    PMDS                    Jamin *et al.* \[[@dvz017-B31]\]; Orvis *et al.* \[[@dvz017-B36]\]
  *Ctnnb1* (*beta-catenin*)   Conditional KO                    PMDS                    Kobayashi *et al.* \[[@dvz017-B41]\]
  *Gata4*                     Binding site mutant or deletion   Normal MD regression    Bouchard *et al.* \[[@dvz017-B26]\]
  *Mmp2*                      Null                              Normal MD regression    Roberts *et al.* \[[@dvz017-B44]\]
  *Smad1/5/8*                 Conditional KO                    PMDS                    Orvis *et al.* \[[@dvz017-B36]\]
  *Sp7* (*Osterix*)           Null                              Delayed MD regression   Mullen *et al.* \[[@dvz017-B42]\]
  *Wif1*                      Null                              Normal MD regression    Park *et al.* \[[@dvz017-B46]\]
  *Wnt7a*                     Null                              PMDS                    Parr and McMahon \[[@dvz017-B34]\]

Conditional KO, Müllerian duct mesenchyme-specific knockout; MD, Müllerian duct; null, full body knockout; PMDS, persistent Müllerian duct syndrome.

Müllerian Ducts Form in Both Male and Female Embryos
====================================================

During fetal development, the Wolffian and Müllerian ducts form in both males and females. The Müllerian ducts can differentiate into the oviduct, uterus, and a portion of the vaginal canal. The Wolffian ducts can differentiate into vasa deferentia, epididymides, seminal vesicles, and the ejaculatory ducts. The Müllerian duct is a mesoepithelial tissue that requires the Wolffian duct for its development \[[@dvz017-B10], [@dvz017-B11]\]. Müllerian duct formation begins shortly after the Wolffian duct forms, taking place in three phases: initiation, invagination, and elongation \[[@dvz017-B11]\]. Initiation consists of the specification of mesonephric epithelial cells to become Müllerian duct cells, characterized by *Lhx1* expression, at about E11.75 in mice. During the invagination phase, the *Lhx1*+ cells form an invagination that makes contact with the Wolffian duct. The Müllerian duct then elongates along the Wolffian duct \[[@dvz017-B12]\]. During Müllerian duct elongation, cell proliferation is observed throughout the duct with more proliferating cells at the growing tip. The Müllerian duct crosses the Wolffian duct at E12.5 to gain a medial position and subsequently fuses with the urogenital sinus at E13.5 \[[@dvz017-B13]\]. *Wnt9b* is expressed in the Wolffian duct \[[@dvz017-B14]\]. *Wnt9b* knockout mice form Wolffian ducts but do not elongate the Müllerian ducts, suggesting a molecular mechanism for the requirement of the Wolffian duct for Müllerian duct development \[[@dvz017-B14]\]. Shortly after the Müllerian ducts form, sex differentiation proceeds. In females, the Müllerian system continues to develop into the uterus, oviducts and a portion of the vagina. However, in males the Müllerian ducts are actively eliminated.

Müllerian Duct Regression Occurs in Male Embryos
================================================

A major event in male sex differentiation is Müllerian duct regression. Mesenchyme--epithelia interactions mediate this process to ensure that oviducts and a uterus do not develop within the male body \[[@dvz017-B15]\]. The cells of the Müllerian duct have a mesoepithelial character during regression \[[@dvz017-B11]\]. Regression begins shortly after the Müllerian duct connects to the urogenital sinus at E13.5 in the mouse and is completed by birth. Early stages of regression can be observed by tightly condensed mesenchymal cells surrounding the Müllerian duct with intercellular spaces located more radially \[[@dvz017-B16], [@dvz017-B17]\]. Müllerian duct regression is proposed to occur through at least three mechanisms: epithelial cell migration, epithelial to mesenchymal transformation, and apoptosis \[[@dvz017-B18]\]. Apoptosis is initially detected in the rostral region of the Müllerian duct and subsequently in intermediate and caudal regions \[[@dvz017-B18]\]. Disruptions in the Müllerian duct basement membrane are followed by epithelial cell entrance into the mesenchymal compartment \[[@dvz017-B18]\]. The regression of the Müllerian duct is proposed to occur in a rostral to caudal manner \[[@dvz017-B15]\].

Genes That Regulate Müllerian Duct Regression
=============================================

Anti-Müllerian Hormone (*Amh*)
------------------------------

The first gene knockout in the AMH signaling pathway was in the *Amh* locus \[[@dvz017-B21]\]. Males homozygous for the targeted *Amh* mutation did not regress the Müllerian ducts, resulting in the development of a uterus, oviducts, and vaginal tissue ([Fig. 1](#dvz017-F1){ref-type="fig"}). These mutant males had correctly descended testes and Wolffian duct derivatives, including seminal vesicles, vasa deferentia, and epididymides. Only ∼10% of the mutant males were fertile. However, sperm from the mutant epididymides were competent to fertilize oocytes *in vitro*. These genetic findings demonstrate that *Amh* produced by the fetal testes is essential for Müllerian duct regression.

![PDMS in the mouse. Dissected reproductive tract organs from control (top) and *Amh* homozygous mutant (bottom) males. In the mutant, the uterine horns (long arrow) and vas deferens (short arrow) parallel each other down to the testes (t) because of a common connective tissue. In this dissection, the connective tissue has been cut to reveal the dual nature of the reproductive tract. Note that because of the physical constraints imposed by the vas deferens, the uterine horns project caudally instead of rostrally. Images from Behringer \[[@dvz017-B21]\]](dvz017f1){#dvz017-F1}

The *cis*-regulation of *Amh* transcription was studied *in vitro* and *in vivo* \[[@dvz017-B22], [@dvz017-B23]\]. *In vitro* studies identified interactions of the nuclear hormone receptor steroidogenic factor 1 (SF1) also known as Ad4-binding protein (Ad4BP) or NR5A1 with a 20-bp sequence just upstream of the TATAA motif that is required for *Amh* transcription \[[@dvz017-B23]\]. About 50-bp upstream of the SF1-binding site is a conserved binding site for the high-mobility group transcription factor SOX9 for activation of *Amh* transcription \[[@dvz017-B24]\]. SF1- and SOX9-binding site mutations were introduced into the endogenous *Amh* locus by gene targeting in embryonic stem (ES) cells \[[@dvz017-B22]\]. Surprisingly, males homozygous for the SF1-binding site mutation had normal Müllerian duct regression. Molecular studies showed that *Amh* transcript levels in fetal and postnatal testes were 3-fold lower in comparison to wild type. Thus, the SF1-binding site regulates *Amh* transcript levels. In contrast, males homozygous for the SOX9-binding site mutation were a phenocopy of the *Amh*-null male phenotypes, i.e. PMDS. These findings suggest that SF1 regulates *Amh* transcript levels and SOX9 is essential for the activation of *Amh* transcription.

There are also multiple GATA-binding sites 5′ of the *Amh* transcriptional start site \[[@dvz017-B25]\]. Recently, male mice homozygous for a 2-bp mutation in one of the GATA-binding sites that abolishes GATA binding (termed *GATAmut*) were generated, using CRISPR genome editing \[[@dvz017-B26]\]. *GATAmut* homozygotes were found to have a 50% reduction in *Amh* transcripts in their testes \[[@dvz017-B26]\]. In addition, a 40-bp deletion that included the GATA-binding site and an adjacent SF1-binding site resulted in a 90% reduction in testicular *Amh* transcripts. Although there was a dramatic reduction in *Amh* transcripts, both types of adult mutant males did not retain Müllerian duct derivatives. Apparently, there are still sufficient levels of AMH for Müllerian duct regression in these mouse mutants.

Anti-Müllerian Hormone Receptor 2 (*Amhr2*)
-------------------------------------------

A 21-day-old rat Sertoli cell cDNA, encoding the type II receptor for AMH, *Amhr2*, was first reported by Baarends *et al.* \[[@dvz017-B5]\]. Their conclusion was based on protein domain structure, indicating a transmembrane serine/threonine kinase receptor and expression localized in the Müllerian duct of male and female fetuses. *Amhr2* transcripts were detected in the mesenchyme adjacent to the Müllerian duct epithelium during embryogenesis, suggesting that the target cell for AMH action is the Müllerian duct mesenchyme. *Amhr2* is also expressed in the fetal and postnatal gonads, specifically in Sertoli and granulosa cells \[[@dvz017-B5], [@dvz017-B22], [@dvz017-B27]\].

A targeted mutation in the mouse *Amhr2* gene was generated by gene targeting in ES cells \[[@dvz017-B30]\]. Approximately 4.4 kb of *Amhr2*, including exons 1--6, was deleted, replacing these sequences with a neomycin resistance gene expression cassette. Homozygous mutant males were normal in size, had correctly descended testes, and differentiated derivatives of the Wolffian ducts. All of the homozygous mutant males also developed a uterus, oviducts, and partial vagina in addition to their male reproductive organ system. This was a phenocopy of *Amh*-null male mice. Some of the homozygous mutant males were fertile. In addition, two other *Amhr2* loss-of-function alleles have been generated, including *Cre* and *lacZ* knock-ins \[[@dvz017-B17], [@dvz017-B31]\]. Both alleles result in a persistence of Müllerian duct derivatives in homozygous mutant males. These findings demonstrate that *Amhr2* is required for Müllerian duct regression.

The transcriptional regulation of *Amhr2* has been explored \[[@dvz017-B32], [@dvz017-B33]\]. *Wt1* encodes a zinc finger transcription factor. A microarray analysis of ∼E11.0 *Wt1* wild-type and null urogenital ridges identified *Amhr2* as a candidate gene regulated by *Wt1*. *Wt1* and *Amhr2* were found to be co-expressed in the urogenital ridge. Three WT1-binding sites are within 100-bp of the *Amhr2* transcriptional start site. Biochemical and *in vitro* studies showed that these sequences bind WT1 and act together to regulate *Amhr2* transcription. More studies are required to determine if these sequences are required for *Amhr2* transcription *in vivo* for Müllerian duct regression.

*Wnt7a* in the Müllerian Duct Epithelium Induces *Amhr2* Expression in Adjacent Mesenchyme
------------------------------------------------------------------------------------------

*Wnt7a* was identified as a gene required for Müllerian duct regression \[[@dvz017-B34]\]. *Wnt7a* is expressed in the Müllerian duct epithelium in both male and female mice from E12.5 to E14.5 \[[@dvz017-B34]\]. Expression continues in the Müllerian ducts of females as they differentiate into the oviducts and uterus. *Wnt7a*-null males are born with Müllerian duct derivatives \[[@dvz017-B34]\]. *In-situ* hybridization analysis of the mutant males showed that *Amhr2* expression was detected in testes but absent in the Müllerian duct mesenchyme \[[@dvz017-B34]\]. This suggests that the essential function of *Wnt7a* in the *Amh* pathway is to activate *Amhr2* transcription in the Müllerian duct mesenchyme \[[@dvz017-B34]\]. Thus, *Wnt7a* expressed in the Müllerian duct epithelium signals to the adjacent mesenchyme that induces *Amhr2* transcription making the Müllerian ducts competent to respond to AMH for regression \[[@dvz017-B34]\].

*Bmpr1a* and *Acvr1* Encode Type I Receptors That Mediate AMH Signaling
-----------------------------------------------------------------------

The transforming growth factor (TGF)-beta superfamily consists of \>30 cytokines \[[@dvz017-B35]\]. However, only seven type I receptors have been identified. Thus, TGF-beta family members must share type I receptors to mediate their signal transduction. Two TGF-beta type 1 superfamily receptor genes, *Acvr1* and *Bmpr1a*, have been identified as AMH receptors for Müllerian duct regression \[[@dvz017-B36]\]. *Acvr1*- and *Bmpr1a*-null mice are embryonic lethal before the Müllerian ducts form \[[@dvz017-B37], [@dvz017-B38]\]. Thus, tissue-specific knockouts were generated. When *Bmpr1a* was knocked out in the Müllerian duct mesenchyme of male mice, Müllerian duct retention was observed in ∼50% of the mutants \[[@dvz017-B31], [@dvz017-B36]\]. This Müllerian duct retention phenotype was identical to the phenotype observed for *Amh* and *Amhr2* knockout males. All males with a conditional knockout of *Acvr1* in the Müllerian duct mesenchyme had Müllerian duct regression \[[@dvz017-B36]\]. However, when both *Acvr1* and *Bmpr1a* were both knocked out in the Müllerian duct mesenchyme, 100% of the male mutants retained the Müllerian ducts, forming the uterus and oviducts \[[@dvz017-B36]\]. These results suggest that *Acvr1* and *Bmpr1a* act redundantly in the *Amh*-induced Müllerian duct regression pathway.

*Smad1*, *Smad* *5*, and *Smad8* Act Redundantly to Mediate AMH Signaling
-------------------------------------------------------------------------

*Smad* activity has been shown to contribute to Müllerian duct regression within the *Amh* pathway. *Smad1*, *Smad5*, and *Smad8* (also known as *Smad9*) are all expressed in the Müllerian duct mesenchyme \[[@dvz017-B39], [@dvz017-B40]\]. A conditional knockout of *Smad1* in the Müllerian duct mesenchyme resulted in proper Müllerian duct regression, as did a conditional *Smad1*/*Smad8* knockout \[[@dvz017-B36]\]. Conditional knockouts of *Smad1* or *Smad8* combined with a *Smad5* conditional knockout resulted in partial Müllerian duct retention \[[@dvz017-B36]\]. This consisted of only part of the Müllerian duct being retained: caudally, rostrally, and/or on one side. The triple conditional knockout of *Smad1/Smad5/Smad8*, however, resulted in fully retained Müllerian duct derivatives \[[@dvz017-B36]\]. Therefore, the three *Smad* genes function redundantly within the pathway, likely downstream of *Acvr1* and *Bmpr1a.*

Beta-Catenin Is Required for MD Regression
------------------------------------------

Multiple *Wnt* genes are expressed in the mesonephros, including *Wnt4*, *Wnt5a*, *Wnt7a*, and *Wnt9b* (gudmap.org). To determine if the canonical WNT pathway was required for Müllerian duct regression, a Müllerian duct mesenchyme-specific knockout of β-catenin was performed \[[@dvz017-B41]\]. Loss of beta-catenin in the Müllerian duct mesenchyme resulted in the persistent Müllerian duct phenotype in all male mutants. Additionally, AMH was found to be expressed in the Sertoli cells of the mutant testes, implying that loss of β-catenin disrupts the pathway downstream of AMH expression \[[@dvz017-B41]\]. These results suggest that β-catenin functions specifically in the Müllerian duct mesenchyme to mediate Müllerian duct regression downstream of AMH signaling \[[@dvz017-B41]\].

*Osterix* Is an AMH-Induced Regulator of Müllerian Duct Regression
------------------------------------------------------------------

A transcriptome analysis of RNA-seq data generated from purified E14.5 male and female Müllerian duct mesenchyme identified *Osterix* (*Osx*), also known as *Sp7*, as a male-enriched gene \[[@dvz017-B42]\]. *Osx* was originally identified as a gene required for osteoblast differentiation \[[@dvz017-B43]\]. *Osx* is expressed in a sexually dimorphic manner in the Müllerian duct mesenchyme. At E14.5, *Osx* expression is detected in the Müllerian ducts of male fetuses, whereas no expression was detected in the Müllerian ducts of female fetuses \[[@dvz017-B42]\]. This male-specific expression continues throughout the remaining regression process \[[@dvz017-B42]\]. In addition, *Osx* expression is lost in male mice lacking *Amhr2* \[[@dvz017-B42]\]. In contrast, overexpression of human AMH in females, using an *MT*-*hAMH* transgene stimulates *Osx* transcription \[[@dvz017-B42]\]. This *Amh*- and *Amhr2*-dependent, sex-specific expression implies a role for *Osx* in the *Amh* signaling pathway. Additionally, loss of *ß*-*catenin* expression leads to a reduction in *Osx* transcripts, implying that *Osx* is downstream of *ß-catenin* in the regression pathway \[[@dvz017-B42]\]. *Osx* knockout males have a 24-h delay in Müllerian duct regression \[[@dvz017-B42]\]. When compared to wild-type males, *Osx* knockout males showed longer and thicker segments of the Müllerian duct at E15.5, E16.5, and E17.5 but complete regression by E18.5 \[[@dvz017-B42]\]. Taken together, the data suggest that *Osx* is an AMH-induced gene that contributes to Müllerian duct regression.

Other Genes That May Be Involved in Müllerian Duct Regression
-------------------------------------------------------------

*Mmp2* (matrix metallopeptidase 2) transcripts are detected in the male Müllerian duct mesenchyme \[[@dvz017-B44]\]. *Mmp2* expression in the Müllerian duct mesenchyme is lost in *Amh*^−/−^ male mouse fetuses at E13 and E14 \[[@dvz017-B44]\]. Pharmacological inhibition of *Mmp2 in vitro* blocks Müllerian duct regression in male urogenital organ culture \[[@dvz017-B44]\]. Knockdown of *Mmp2* using morpholino oligonucleotides also resulted in Müllerian duct regression defects in male urogenital organ culture. In contrast, activation of MMPs resulted in Müllerian duct regression in female urogenital organ culture. However, male *Mmp2* mutant mice have normal Müllerian duct regression \[[@dvz017-B44]\], suggesting that *Mmp2* is not essential for Müllerian duct regression *in vivo* or may act redundantly perhaps with other *Mmp* genes.

*Wif1* (WNT inhibitory factor 1) is a secreted frizzled-related protein that inhibits WNT signaling by binding WNT, blocking binding to receptors \[[@dvz017-B45]\]. *Wif1* expression is detected in the male Müllerian duct but not the female at E13.5 and E14.5 \[[@dvz017-B46]\]. *Wif1* transcripts are not detected in *Amhr2*^−/−^ male fetuses at E13.5 \[[@dvz017-B46]\]. Exogenous AMH can induce *Wif1* expression in the Müllerian duct mesenchyme in female urogenital organ culture. Knockdown of *Wif1* expression by siRNA *in vitro* inhibits Müllerian duct regression \[[@dvz017-B46]\]. However, newborn and 4-week-old *Wif1* knockout male mice did not have residual Müllerian tissues, suggesting that *Wif1* is not essential for Müllerian duct regression *in vivo* or there is gene redundancy.

GRNs Describe Pathways That Regulate Biological Processes
---------------------------------------------------------

GRNs can be described as control systems, at the genetic level, for living creatures. They can include, but are not limited to, DNA sequence-specific transcription factors and downstream genes. The network consists of the processes by which gene products and sequences function collectively to fulfill a biological task. The gene sequences in this case are targets of transcription factors, including enhancers, insulators, and silencers \[[@dvz017-B47]\]. GRNs are particularly paramount in development. GRNs, for example, specify morphological structures in organisms by dictating the timing and development of cells and tissues that make up a structure \[[@dvz017-B48]\]. GRNs, therefore, can be uncovered and visualized to illuminate the proper development and function of an organism. When mapped, a GRN can display nodes, feedback loops, enhancement, inhibition, and much more to represent genetic regulation. Regulatory information placed into GRNs is first uncovered and supported through experimentation. Nodes are often defined from knockout or knockdown experiments, which show that a gene is required for function of the network. Further experimentation then specifies genes that encode regulators of those required genes or regulatory sequences within the genome. Once a GRN has begun to be mapped, it can be used to generate hypotheses for the GRN or biological process affected by the GRN. A GRN from one species can be compared to other GRNs across species for evolutionary study, as GRNs hold the modifications that differentiate one species from another \[[@dvz017-B48]\]. Medically, GRNs dictate normal bodily function and are, therefore, effective aids in finding causes and solutions for disease. Considering sexual development particularly, GRNs provide information needed to understand how organisms become sexually differentiated. In the case of this review, we will define our GRN using the studies by Eric Davidson as a guide \[[@dvz017-B49]\].

A GRN for Müllerian Duct Regression
-----------------------------------

Based on the genetic and molecular evidence presented above, we present the first GRN for AMH-induced Müllerian duct regression ([Fig. 2](#dvz017-F2){ref-type="fig"}). Sertoli cells of the fetal testes express *Sf1/Nr5a1*, *Gata4*, and *Sox9*, encoding transcription factors that directly bind the 5′ region of the *Amh* locus. These are among the very few direct interactions between transcription factors and *cis*-regulatory elements for genes in the GRN. Müllerian duct epithelial cells express and secrete WNT7A that interacts with the adjacent mesenchyme cells to induce the expression of *Amhr2*, making the mesenchyme competent to respond to AMH. AMH secreted by fetal Sertoli cells interacts with AMHR2/BMPR1A/ACVR1, resulting in phosphorylation of SMAD1/5/8. The transcriptional targets of these SMADs are currently unknown. The requirement of beta-catenin in mesenchyme for Müllerian duct regression suggests that canonical WNT signaling may be required. Beta-catenin regulates *Osx* transcript levels but there are other inputs for *Osx* transcription. Transcriptome comparisons between male and female Müllerian duct mesenchyme have identified numerous genes that are upregulated in males relative to females \[[@dvz017-B42], [@dvz017-B46]\]. These provide candidate genes to be investigated for their roles in Müllerian duct regression. The GRN indicates that environmental influences that alter Amh transcriptional regulators (SOX9, NR5A1, and GATA4) could alter Müllerian duct regression. However, more studies are required to investigate how environmental factors might alter transcriptional outputs within the Müllerian duct mesenchyme. In conclusion, this *Amh*-regulated GRN provides a tool to investigate Müllerian duct regression, male sex differentiation, and how it may relate to environmental influences.

![a GRN for AMH-induced Müllerian duct regression. The GRN is divided into domains, representing specific fetal cell types. The interactions contained within a domain occur within that cell type. Each gene in the GRN is depicted as a short horizontal line from which extends a bent arrow indicating transcription. The name of each gene is below the horizontal line. Arrows extending from the transcription arrow of one gene to the horizontal line of another gene indicate transcription factor binding to *cis*-regulatory elements to enhance transcription. Double arrows between cell-type domains indicate intercellular signaling of a protein. Circles in the GRN indicate intracellular protein activity. White circles indicate multiprotein complexes. Black circles indicate phosphorylation of a protein. Arrows formed by dotted lines indicate interactions that have been observed *in vitro* but not yet confirmed *in vivo*. Boxes containing question marks indicate a predicted site of regulation that has not yet been determined](dvz017f2){#dvz017-F2}
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